ESMO 2019: Kisqali shows superior overall survival in breast cancer
Kisqali is the only CDK4/6 inhibitor to demonstrate positive overall survival in two pivotal Phase III trials. Credit: Novartis AG.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more